Induction of apoptosis by buckwheat trypsin inhibitor in chronic myeloid leukemia K562 cells

被引:15
|
作者
Wang, Zhuan-Hua [1 ]
Gao, Li
Li, Yu-Ying
Zhang, Zheng
Yuan, Jing-Ming
Wang, Hong-Wei
Zhang, Li
Zhu, Lei
机构
[1] Shanxi Univ, Inst Biotechnol, Minist Educ, Key Lab Chem Biol & Mol Engn, Taiyuan 030006, Peoples R China
[2] Shanxi Med Univ, Hosp 2, Ctr Blood, Taiyuan 030001, Peoples R China
关键词
trypsin inhibitor; buckwheat; K562; cell; apoptosis;
D O I
10.1248/bpb.30.783
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Buckwheat is an ancient and specialty grain in China. Due to its unique chemical and bio-activity components, buckwheat has been found to have many uses in food products and medicine. However, very little is known about the toxicity of protease inhibitors from buckwheat. Here, the possible effects of a recombinant buckwheat trypsin inhibitor (rBTI) on the induction of apoptosis of the human K562 cell line were investigated by MTT (3[4,5-dimethylthiazol-2-yll-2,5-diphenyltetrazolium bromide) assays and flow cytometric analysis. MTT assay showed that rBTI could specifically inhibit the growth of K562 cells in a dose-dependent manner, but there were minimal effects on normal human peripheral blood mononuclear cells (PBMCs). Furthermore, comparison the effects of rBTI on K562 cells with those of negative control (BSA and the complex of BSA and rBTI) revealed that rBTI was highly toxic to K562 cells, and BSA hardly had any inhibition on proliferation in K562 cells. The analysis of flow cytometric indicated that the apoptosis of K562 cells were 31.0%, 32.8%, 35.3% and 52.1% after treated by rBTI in range of 12.5-100 Elg/ml, respectively. The results suggested that rBTI can induce apoptosis of K562 cells and that it might be a potential protein drug of the trypsin inhibitor family.
引用
收藏
页码:783 / 786
页数:4
相关论文
共 50 条
  • [41] Dihydroartemisinin downregulates vascular endothelial growth factor expression and induces apoptosis in chronic myeloid leukemia K562 cells
    Lee, J
    Zhou, HJ
    Wu, XH
    [J]. CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2006, 57 (02) : 213 - 220
  • [42] MECHANISMS OF APOPTOSIS INDUCTION OF QUORUM-SENSING AUTOINDUCER ANALOGUES AGAINST CHRONIC MYELOID LEUKEMIC K562 CELLS
    Hazawa, M.
    Kudo, M.
    Igarashi, J.
    Suga, H.
    Kashiwakura, I.
    [J]. EXPERIMENTAL HEMATOLOGY, 2010, 38 (09) : S23 - S23
  • [43] Puerarin leads to K562 cell apoptosis of chronic myelogenous leukemia via induction of autophagy
    Gao, Da
    Xiao, Zhen
    Li, Hui-ping
    [J]. JOURNAL OF BUON, 2017, 22 (06): : 1554 - 1562
  • [44] Mitomycin induced apoptosis in human leukemia K562 cells
    Shao, Shu-Li
    Zhao, Bin
    Zhang, Wei-Wei
    Zhao, Wei
    Wu, Guang-hui
    Song, Jin-ping
    [J]. ADVANCES IN ENVIRONMENTAL ENGINEERING, 2012, 599 : 71 - 75
  • [45] Apoptosis Induction of K562 Cells by Lymphocytes: An AFM Study
    Jin, Hua
    Zhao, Hongxia
    Liu, Li
    Jiang, Jinhuan
    Wang, Xiaoping
    Ma, Shuyuan
    Cai, Jiye
    [J]. SCANNING, 2013, 35 (01) : 7 - 11
  • [46] Silymarin inhibited proliferation and induced apoptosis in human chronic myeloid leukemia cell line K562
    Faezizadeh, Zohreh
    Namin, Alireza Mesbah
    Allameh, Abdolamir
    [J]. CLINICAL BIOCHEMISTRY, 2011, 44 (13) : S115 - S115
  • [47] Induction of apoptosis and regulation of the MAPK pathway by ursolic acid in human leukemia K562 cells
    Liu, Xiao-Shan
    Jiang, Jikai
    [J]. PLANTA MEDICA, 2007, 73 (11) : 1192 - 1194
  • [48] Cytotoxic effects of resveratrol on imatinib sensitive and resistant K562 chronic myeloid leukemia cells
    Can, G.
    Baran, Y.
    [J]. EJC SUPPLEMENTS, 2010, 8 (05): : 148 - 148
  • [49] APOPTOTIC EFFECTS OF RESVERATROL ON IMATINIB SENSITIVE AND RESISTANT K562 CHRONIC MYELOID LEUKEMIA CELLS
    Baran, Y.
    Can, G.
    [J]. HAEMATOLOGICA-THE HEMATOLOGY JOURNAL, 2010, 95 : 351 - 352
  • [50] Inhibition of thioredoxin reductase by auranofin induces apoptosis in adriamycin-resistant human K562 chronic myeloid leukemia cells
    Liu, Jing-Jing
    Liu, Qing
    Wei, Hu-Lai
    Yi, Juan
    Zhao, Huai-Shun
    Ga, Li-Ping
    [J]. PHARMAZIE, 2011, 66 (06): : 440 - 444